Home › Compare › BEUT vs MRK

BEUT vs MRK: Dividend Comparison 2026

BEUT yields 2000000.00% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BEUT wins by $4.879226400974806e+39M in total portfolio value
10 years
BEUT
BEUT
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full BEUT calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — BEUT vs MRK

📍 BEUT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBEUTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BEUT + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BEUT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BEUT
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, BEUT beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BEUT + MRK for your $10,000?

BEUT: 50%MRK: 50%
100% MRK50/50100% BEUT
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BEUT
No analyst data
Altman Z
-98.0
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BEUT buys
0
MRK buys
0
No recent congressional trades found for BEUT or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBEUTMRK
Forward yield2000000.00% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$4.879226400974806e+39M$30.7K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$950.29
Total dividends collected$4.879195005460081e+39M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BEUT vs MRK ($10,000, DRIP)

YearBEUT PortfolioBEUT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,192$351.54+$200.00M → BEUT
2$3,738,731,768,458$3,738,517,757,009.35$12,524$392.70+$3738731.76M → BEUT
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,015$438.65+$65315062866.92M → BEUT
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$15,682$489.96+$1066400830062625.00M → BEUT
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$17,547$547.23+$16272182796453826560.00M → BEUT
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$19,632$611.16+$2.3205424011366188e+23M → BEUT
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$21,963$682.53+$3.0927990661046884e+27M → BEUT
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$24,571$762.18+$3.8524105697352695e+31M → BEUT
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$27,486$851.08+$4.484688260147987e+35M → BEUT
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$30,745$950.29+$4.879226400974806e+39M → BEUT

BEUT vs MRK: Complete Analysis 2026

BEUT — Stock

Science to Consumers, Inc., a development stage company, focuses on marketing and selling formulated anti-aging cream products under the DermaLastyl name; and distributing Argan oil products. It intends to sell its products to individual customers and commercial customers, such as spas, stores, and massage therapy offices. The company was formerly known as Argan Beauty Corporation and changed its name to Science to Consumers, Inc. in December 2014. Science to Consumers, Inc. was founded in 2013 and is based in Guangzhou, China.

Full BEUT Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this BEUT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BEUT vs SCHDBEUT vs JEPIBEUT vs OBEUT vs KOBEUT vs MAINBEUT vs JNJBEUT vs ABBVBEUT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.